The FDA approved the first mRNA flu vaccine for use in older adults. Here’s what to know

For the first time, Americans aged 50 and older will have access to a flu vaccine powered by mRNA technology. Developed by Moderna, the shot known as mFlusiva received Food and Drug Administration approval last week, marking a significant shift from traditional manufacturing methods.

The approval process was not without hurdles. The FDA initially hesitated to review the application, and the technology has faced political headwinds regarding federal funding. However, an independent panel of experts eventually voted unanimously that the vaccine's protective benefits outweigh any potential risks.

How mRNA Changes the Game

Traditional flu shots rely on growing weakened viruses in chicken eggs or specialized cells, a process that requires scientists to select target strains as early as February. This six-month lead time often results in a 'mismatch' if the virus mutates by the time flu season actually arrives.

Because mRNA vaccines can be manufactured much faster, researchers can wait until May to finalize the strains. This flexibility allows for a more accurate match with the viruses currently circulating, potentially increasing the shot's overall effectiveness.

Efficacy and Side Effects

Data from a study involving 40,000 participants showed the mRNA option was roughly 27% more effective than standard shots during the previous season. While it produced higher rates of temporary side effects like headaches and injection site pain, most reactions were mild and brief.

The FDA granted standard approval for those aged 50 to 64, while adults 65 and older fall under an accelerated approval pathway. This requires Moderna to conduct further studies this season to confirm that the vaccine provides superior clinical protection compared to high-dose shots usually reserved for seniors.

Availability and Insurance Questions

Moderna plans to have mFlusiva ready for the autumn rollout, but finding it might be tricky. Since many clinics and pharmacies order their supplies months in advance, availability may be limited to major chains like CVS or Walgreens in the early stages.

There is also a lingering question regarding insurance coverage. A recent legal dispute has stalled meetings for the CDC's vaccine advisory committee, meaning a formal recommendation is pending. Without this guidance, it remains unclear if all private insurance plans will cover the new shot with zero copay.

Medical experts stress that despite these logistical hurdles, the vaccine remains a vital tool. With older adults accounting for over 70% of flu-related deaths, any advancement in vaccine accuracy could save thousands of lives annually.